Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma

Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma

Background Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key drivers of type 2 inflammation. In the phase 3 LIBERTY ASTHMA QUEST trial (NCT02414854) in patients with uncontrolled, moderate-to-severe asthma, add-on dupilumab 2...

Full description

Bibliographic Details
Main Authors: Mario Castro, Klaus F. Rabe, Jonathan Corren, Ian D. Pavord, Constance H. Katelaris, Yuji Tohda, Bingzhi Zhang, Megan S. Rice, Jaman Maroni, Paul Rowe, Gianluca Pirozzi, Nikhil Amin, Marcella Ruddy, Bolanle Akinlade, Neil M.H. Graham, Ariel Teper
Format: Article
Language:English
Published: European Respiratory Society 2020-01-01
Series:ERJ Open Research
Online Access:http://openres.ersjournals.com/content/6/1/00204-2019.full

Internet

http://openres.ersjournals.com/content/6/1/00204-2019.full

Similar Items